Find the information you need on the hepatitis and therapeutics industry. Our collection of research reports provides insights into drug development, analyses and opportunities with specifics on market share, segmentation, size and growth in the US and global markets are also featured.
All reports in Hepatitis
|
Chinese Markets for Hepatitis Drugs
4/1/2012 | published by: Asia Market Information & Development Company
... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers in ...
|
more...
|
$4,000.00
|
|
The 2012 Hepatitis Diagnostics Market: US, Europe, JapanTest Volume, Sales Forecasts and Supplier Shares by Country
3/28/2012 | published by: Venture Planning Group
... report provides the 5- and 10-year test volume and sales forecasts by country for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in ...
|
more...
|
$8,750.00
|
|
Hepatitis A – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Hepatitis A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis A. 'Hepatitis A - Pipeline Review, H1 2012' ...
|
more...
|
$500.00
|
|
Infection Control in Ambulatory Care
3/1/2012 | published by: Apollo Managed Care Consultants
... meet OSHA, Joint Commission, NCQA and other standards for accreditation and certification visits in a medical office or an ambulatory care setting. Resources include forms, OSHA standards, Surgical safety checklist; web links, references. Updated annually.
|
more...
|
$65.00
|
|
Hepatitis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. 'Hepatitis - Pipeline Review, H1 2012' is built using data and information ...
|
more...
|
$500.00
|
|
Hepatitis B – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... for Hepatitis B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis B. 'Hepatitis B - Pipeline Review, H1 2012' ...
|
more...
|
$500.00
|
|
Hepatitis C – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. 'Hepatitis C - Pipeline Review, H1 2012' ...
|
more...
|
$500.00
|
|
Molecular Diagnostics in Infectious Disease Testing
2/1/2012 | published by: TriMark Publications
... one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics--along with the development of microarray devices to measure analytes in the blood--has led to this revolutionary market ...
|
more...
|
$3,400.00
|
|
Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
1/23/2012 | published by: Renub Research
... will be driven primarily by the launch of novel premium-priced agents that will increase the size of the drug-treated population, mainly as a result of the re-treatment of prior non-responder patients. Pegasys, Copegus and Pegintron ...
|
more...
|
$975.00
|
|
Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market
1/1/2012 | published by: GBI Research
... Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market”, provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the ...
|
more...
|
$3,500.00
|
|
Liver Disease Treatments: The Global Market
1/1/2012 | published by: BCC Research
... stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors). The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016. The U.S. ...
|
more...
|
$4,850.00
|
|
Global Hepatitis Diagnostics Market: Growth Opportunities and Business Expansion Strategies
11/28/2011 | published by: Venture Planning Group
... report provides the 5- and 10-year test volume and sales forecasts by country for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in ...
|
more...
|
$8,750.00
|
|
Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
10/31/2011 | published by: GlobalData
... is an essential source of information and analysis on the global hepatitis b vaccines market. The report identifies the key trends shaping and driving the global hepatitis b vaccines market. The report also provides insights ...
|
more...
|
$3,500.00
|
|
Hepatitis A Global Clinical Trials Review, H2, 2011
10/30/2011 | published by: GlobalData
... and data relating to the clinical trials on Hepatitis A. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...
|
more...
|
$1,000.00
|
|
Hepatitis C Global Clinical Trials Review, H2, 2011
10/30/2011 | published by: GlobalData
... and data relating to the clinical trials on Hepatitis C. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...
|
more...
|
$1,000.00
|
|
Hepatitis A - Pipeline Review, H2 2011
10/26/2011 | published by: Global Markets Direct
... for Hepatitis A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis A. 'Hepatitis A - Pipeline Review, H2 2011' ...
|
more...
|
$500.00
|
|
Hepatitis B Global Clinical Trials Review, H2, 2011
10/11/2011 | published by: GlobalData
... and data relating to the clinical trials on Hepatitis B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...
|
more...
|
$1,000.00
|
|
U.S. Hepatitis C Market
10/11/2011 | published by: Frost & Sullivan
... challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: interferons, protease inhibitors, nucleotide polymerase inhibitors, non-nucleotide polymerase inhibitors, NS5a's, and other classes. Included are examinations of therapeutic candidates ...
|
more...
|
$6,000.00
|
|
Hepatitis C - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. 'Hepatitis C - Pipeline Review, H2 2011' ...
|
more...
|
$500.00
|
|
Hepatitis - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. 'Hepatitis - Pipeline Review, H2 2011' is built using data and information ...
|
more...
|
$500.00
|
|
Hepatitis B - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... for Hepatitis B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis B. 'Hepatitis B - Pipeline Review, H2 2011' ...
|
more...
|
$500.00
|
|
The Hepatitis Market Outlook to 2016
9/26/2011 | published by: Business Insights
... to be going to change. Introduction This report provides comprehensive coverage of the hepatitis market, incorporating a detailed epidemiological analysis. The report analyzes current leading brands, and profiles leading players in the hetpatitis market. It ...
|
more...
|
$3,835.00
|
|
The Hepatitis Market Outlook to 2016
9/26/2011 | published by: Business Insights
... development and forecasts their expected sales performance. Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes. Compare the franchises of the leading companies in ...
|
more...
|
$3,835.00
|
|
Key Companies: HCV - New market entrants are changing the corporate landscape
8/30/2011 | published by: Datamonitor
... the way for companies that traditionally do not have a presence in HCV to develop the next generation small molecule antivirals.In-depth discussion of portfolios and strategies of key HCV companies. Analysis of recent key deals ...
|
more...
|
$3,800.00
|
|
Key Companies: HCV – New market entrants are changing the corporate landscape
8/30/2011 | published by: Datamonitor
... of Vertex’s Incivek/Incivo (telaprevir) and Merck’s Victrelis (boceprevir) has heralded a new era in the treatment of hepatitis C (HCV). These agents are also changing the HCV corporate landscape by paving the way for companies ...
|
more...
|
$3,800.00
|
